This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/chebi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/wikipedia/
n11http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/pdb/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00151/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00151
rdf:type
n3:Drug
n3:description
A thiol-containing non-essential amino acid that is oxidized to form cystine. [PubChem]
n3:generalReferences
# Bulaj G, Kortemme T, Goldenberg DP: Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry. 1998 Jun 23;37(25):8965-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9636038 # Baker DH, Czarnecki-Maulden GL: Pharmacologic role of cysteine in ameliorating or exacerbating mineral toxicities. J Nutr. 1987 Jun;117(6):1003-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3298579
n3:group
nutraceutical approved
n3:indication
For the prevention of liver damage and kidney damage associated with overdoses of acetaminophen
n3:manufacturer
n7:271B4BFB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n5:DB00151 n11:DB00151
dcterms:title
L-Cysteine
adms:identifier
n13:DB00151 n14:17561 n17:CYS n18:PA449173 n19:C00097 n20:D00026 n21:L-Cysteine
n3:mechanismOfAction
Although classified as a non-essential amino acid cysteine may be essential for infants, the elderly, and individuals with certain metabolic disease or who suffer from malabsorption syndromes. Cysteine can usually be synthesized by the human body under normal physiological conditions if a sufficient quantity of methionine is available. Due to the ability of thiols to undergo redox reactions, cysteine has antioxidant properties. Cysteine's antioxidant properties are typically expressed in the tripeptide glutathione, which occurs in humans as well as other organisms. The systemic availability of oral glutathione (GSH) is negligible; so it must be biosynthesized from its constituent amino acids, cysteine, glycine, and glutamic acid. Glutamic acid and glycine are readily available in the diets of most industrialized countries, but the availability of cysteine can be the limiting substrate. Cysteine is also an important source of sulfide in human metabolism. The sulfide in iron-sulfur clusters and in nitrogenase is extracted from cysteine, which is converted to alanine in the process. In a 1994 report released by five top cigarette companies, cysteine is one of the 599 additives to cigarettes. Its use or purpose, however, is unknown, like most cigarette additives. Its inclusion in cigarettes could offer two benefits: Acting as an expectorant, since smoking increases mucus production in the lungs; and increasing the beneficial antioxidant glutathione (which is diminished in smokers).
n3:packager
n7:271B4BF9-363D-11E5-9242-09173F13E4C5 n7:271B4BF8-363D-11E5-9242-09173F13E4C5 n7:271B4BFA-363D-11E5-9242-09173F13E4C5
n3:synonym
(R)-2-Amino-3-mercaptopropanoic acid (2R)-2-amino-3-sulfanylpropanoic acid Cys (2R)-2-amino-3-mercaptopropanoic acid L-Cys L-2-Amino-3-mercaptopropionic acid
n3:mixture
n15:271B4BEC-363D-11E5-9242-09173F13E4C5 n15:271B4BED-363D-11E5-9242-09173F13E4C5 n15:271B4BF0-363D-11E5-9242-09173F13E4C5 n15:271B4BF1-363D-11E5-9242-09173F13E4C5 n15:271B4BEE-363D-11E5-9242-09173F13E4C5 n15:271B4BEF-363D-11E5-9242-09173F13E4C5 n15:271B4BF4-363D-11E5-9242-09173F13E4C5 n15:271B4BF5-363D-11E5-9242-09173F13E4C5 n15:271B4BF2-363D-11E5-9242-09173F13E4C5 n15:271B4BF3-363D-11E5-9242-09173F13E4C5 n15:271B4BF6-363D-11E5-9242-09173F13E4C5 n15:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Alfred Maierhofer, Hans Wagner, "Process for the production of high purity S-carboxymethyl-L-cysteine." U.S. Patent US4129593, issued May, 1965.
n9:hasConcept
n10:M0005539
n3:IUPAC-Name
n6:271B4C03-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4C09-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4C08-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4C05-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4C06-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4C07-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4C19-363D-11E5-9242-09173F13E4C5 n6:271B4C01-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4C02-363D-11E5-9242-09173F13E4C5 n6:271B4BFF-363D-11E5-9242-09173F13E4C5 n6:271B4C1B-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4C00-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B4C1C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B4C0F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4C10-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4C0A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4C0B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4C0D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4C0C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4C0E-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
52-90-4
n3:category
n3:containedIn
n16:271B4BFE-363D-11E5-9242-09173F13E4C5 n16:271B4BFD-363D-11E5-9242-09173F13E4C5 n16:271B4BFC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4C15-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4C17-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4C18-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B4C1A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4C14-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4C13-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4C16-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4C04-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4C11-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4C12-363D-11E5-9242-09173F13E4C5